A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson's Disease (IPD) patients with motor fluctuations and PD related chronic pain

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Safinamide (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms Pain study
Sponsors Zambon SpA

Most Recent Events

18 May 2021 Status changed from active, no longer recruiting to completed.
11 Jan 2021 Planned End Date changed from 28 Jun 2020 to 30 Apr 2021.
11 Jan 2021 Planned primary completion date changed from 28 Jun 2020 to 30 Apr 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight